# BioAsset > BioAsset is a student-run research platform at the intersection of life sciences and capital markets. A global team of student analysts publishes deep dives, company analyses, educational primers, and open financial models, and interviews leaders across biotech, healthcare finance, and the life sciences. BioAsset (bioasset.info, tagline “Where Medicine Meets Markets”) was founded by Dmitry Vysotskiy. The most important developments in healthcare are driven by capital, science, and policy working together. BioAsset exists to make that intersection legible to the next generation of analysts, investors, and physicians. Key facts: - Research: 47 posts by 10 student analysts. Every post has an article page under https://bioasset.info/research/ - Expert interviews: 9 published, 1 upcoming - Official partner and first client: ReMinded - Fall 2026 curriculum: 11 weeks, from life sciences fundamentals to biotech valuation and M&A - Contact: bioasset@bioasset.info ## Research - [The Quiet (and Growing) Giant of US Healthcare: Cardinal Health](https://bioasset.info/research/the-quiet-and-growing-giant-of-us-healthcare-cardinal-health.html): Alay Galvankar, Company Analysis. Explains how drug distributor Cardinal Health earns thin margins on $254 billion in revenue and why it is growing faster than larger rival McKesson. - [Long Aktis Oncology (AKTS): Investment Pitch](https://bioasset.info/research/long-aktis-oncology-akts-investment-pitch.html): Dmitry Vysotskiy, Investment Pitch. The pitch recommends buying Aktis Oncology (AKTS), a clinical-stage developer of miniprotein radiopharmaceuticals for solid tumors. - [The FDA has approved Takeda’s oveporexton, the first orexin agonist for narcolepsy](https://bioasset.info/research/the-fda-has-approved-takeda-s-oveporexton-the-first-orexin-agonist-for-narcolepsy.html): Joy Wu, FDA Approval. The FDA has approved Takeda's oveporexton, the first orexin agonist for narcolepsy, and drugmakers see wider uses for the orexin pathway. - [Designer-ish Babies: Will it be the Future?](https://bioasset.info/research/designer-ish-babies-will-it-be-the-future.html): Jingqiu Tian, Industry Trends. Looks at startups such as Nucleus Genomics that screen IVF embryos for disease risk and traits like height and IQ, and the ethical debate around them. - [FDA Approves Rasonque: The First RAS-Targeted Drug for Pancreatic Cancer](https://bioasset.info/research/fda-approves-rasonque-the-first-ras-targeted-drug-for-pancreatic-cancer.html): Neev Mohindroo, FDA Approval. The FDA has approved Rasonque, the first RAS-targeted drug for pancreatic cancer, a once-daily pill priced at $477,000 a year. - [The Parkinson’s Bet That Couldn’t Hold $15: Aspen Neuroscience’s IPO](https://bioasset.info/research/the-parkinson-s-bet-that-couldn-t-hold-15-aspen-neuroscience-s-ipo.html): Judy Dalati, Company Analysis. Aspen Neuroscience raised $140.6 million in its IPO for a Parkinson's cell therapy, then fell about 17% below its $15 IPO price within two weeks. - [A $1.3B Bet: Merck KGaA Buys Silence Therapeutics](https://bioasset.info/research/a-1-3b-bet-merck-kgaa-buys-silence-therapeutics.html): Viren Jain, Company Analysis. Merck KGaA agreed to buy Silence Therapeutics for about $1.3 billion, a 130% premium, to gain divesiran, an unapproved siRNA drug for a rare blood cancer. - [From the Space Race to the Biotech Race: China Guards Its Lead](https://bioasset.info/research/from-the-space-race-to-the-biotech-race-china-guards-its-lead.html): Judy Dalati, Industry Trends. China proposed blocking foreign acquisitions of its cell and gene therapy and siRNA platforms, protecting a growing lead in early-stage drug development. - [The Shovel Sellers of AI Biology: Twist Bioscience](https://bioasset.info/research/the-shovel-sellers-of-ai-biology-twist-bioscience.html): Neev Mohindroo, Company Analysis. Twist Bioscience rose 16% to $184 after Leerink named it the top beneficiary of Anthropic's biology push, because every AI-designed protein still has to be built from DNA. - [The Price to Pay to End an mRNA Vaccine Fight: Up to $2.25B to be Paid by Moderna](https://bioasset.info/research/the-price-to-pay-to-end-an-mrna-vaccine-fight-up-to-2-25b-to-be-paid-by-moderna.html): Jingqiu Tian, Company Analysis. Moderna will pay up to $2.25 billion to Arbutus and Genevant to settle a patent dispute over the lipid nanoparticles used in its mRNA vaccines. - [$6.7B: Merck’s Leukemia Drug Acquisition That Could Shake Up The Market](https://bioasset.info/research/6-7b-merck-s-leukemia-drug-acquisition-that-could-shake-up-the-market.html): Alay Galvankar, Company Analysis. Merck is buying Terns Pharmaceuticals for about $6.7 billion to gain TERN-701, an oral leukemia drug that would compete with Novartis' Scemblix. - [UK Biobank: Turning Biological Data into Drug Discovery](https://bioasset.info/research/uk-biobank-turning-biological-data-into-drug-discovery.html): Brendan Seo, Deep Dive. Explains how UK Biobank's health, genetic and lifestyle data from over 500,000 participants supports early-stage drug discovery. - [Saliva, Stress, and Startups: The Rise of Cortisol Testing](https://bioasset.info/research/saliva-stress-and-startups-the-rise-of-cortisol-testing.html): Joy Wu, Industry Trends. Covers the rise of saliva-based cortisol testing, including how it differs from blood tests, the lab methods behind it and the startups involved. - [Tectonic Therapeutic (TECX): Long Thesis Memo & Financial Model](https://bioasset.info/research/tectonic-therapeutic-tecx-long-thesis-memo-financial-model.html): Benjamin Shar, Memo + Model. The memo recommends a long position in Tectonic Therapeutic (TECX), arguing its relaxin drug TX45 is mispriced after rival program failures. - [CRISPR’s Fatal Test: Intellia’s In-Vivo Reality Check](https://bioasset.info/research/crispr-s-fatal-test-intellia-s-in-vivo-reality-check.html): Dmitry Vysotskiy. Intellia paused a Phase III in vivo CRISPR trial after a patient death and the FDA placed a clinical hold, raising safety questions for gene editing. - [$11 Insulin: California Rewrites the Prescription on Big Pharma](https://bioasset.info/research/11-insulin-california-rewrites-the-prescription-on-big-pharma.html): Dmitry Vysotskiy. California's CalRx will sell long-acting insulin pens for about $11 each from January 1, 2026, challenging major insulin makers on price. - [Roche Pill Delays Tumor Progression in Closely Watched Breast Cancer Study](https://bioasset.info/research/roche-pill-delays-tumor-progression-in-closely-watched-breast-cancer-study.html): Dmitry Vysotskiy. Roche's giredestrant plus everolimus cut the risk of breast cancer progression by about 62% in ESR1-mutated patients in the Phase 3 evERA trial. - [Blackstone x TPG Make Hologic Private ($18.3B)](https://bioasset.info/research/blackstone-x-tpg-make-hologic-private-18-3b.html): Dmitry Vysotskiy. Blackstone and TPG will take women's health med-tech company Hologic private in a deal valued at up to $18.3 billion. - [Inside China’s Transformative Global Biotech Boom](https://bioasset.info/research/inside-china-s-transformative-global-biotech-boom.html): Dmitry Vysotskiy. Describes how Chinese biotech firms are moving from generic production to global drug innovation and licensing deals with Western pharma. - [The $30 Million Bet: How Valthos and AI Are Rewriting Biodefense](https://bioasset.info/research/the-30-million-bet-how-valthos-and-ai-are-rewriting-biodefense.html): Dmitry Vysotskiy. OpenAI Startup Fund, Lux Capital and Founders Fund backed Valthos with $30 million to build AI systems for detecting and countering biological threats. - [Eli Lilly vs Novo Nordisk: Who Will Win the GLP-1 Race?](https://bioasset.info/research/eli-lilly-vs-novo-nordisk-who-will-win-the-glp-1-race.html): Dmitry Vysotskiy. Compares Eli Lilly and Novo Nordisk in the GLP-1 market, focusing on the race to bring an effective oral weight-loss pill to patients. - [From Chips to Clinics: Nvidia Expands Its Healthcare Ambitions](https://bioasset.info/research/from-chips-to-clinics-nvidia-expands-its-healthcare-ambitions.html): Dmitry Vysotskiy. Nvidia is expanding into healthcare through AI partnerships with Eli Lilly, Verily, Johnson & Johnson, Innovaccer and the Chan Zuckerberg Initiative. - [Breaking Bones: Inside J&J’s Orthopedics Spinoff](https://bioasset.info/research/breaking-bones-inside-j-j-s-orthopedics-spinoff.html): Dmitry Vysotskiy. Johnson & Johnson plans to spin off its orthopedics business as a standalone company, DePuy Synthes, within 18 to 24 months. - [From One Drop to Fifty Diagnoses: How Blood May Be the Next Frontier of Cancer Detection](https://bioasset.info/research/from-one-drop-to-fifty-diagnoses-how-blood-may-be-the-next-frontier-of-cancer-detection.html): Dmitry Vysotskiy. GRAIL's blood test detected signals for more than 50 cancer types in a trial of over 23,000 symptom-free adults, often at early stages. - [Biotech X Beauty: The Future of Skincare](https://bioasset.info/research/biotech-x-beauty-the-future-of-skincare.html): Dmitry Vysotskiy. Covers biotech-derived skincare, including polynucleotide therapy, personalized products and Debut's $20 million raise for AI ingredient discovery. - [America’s GLP-1 Paradox: Obesity Falls, Diabetes Rises](https://bioasset.info/research/america-s-glp-1-paradox-obesity-falls-diabetes-rises.html): Dmitry Vysotskiy. Gallup data show US adult obesity falling to 37.0% in 2025 as GLP-1 drug use rises, while diabetes diagnoses keep climbing. - [AI’s Early Footprint: Optimized Peptides for Efficient Protein Production](https://bioasset.info/research/ai-s-early-footprint-optimized-peptides-for-efficient-protein-production.html): Dmitry Vysotskiy. Researchers at Nagoya University used AI to find four-amino-acid peptide tags that prevent ribosome stalling and raise protein yields in E. coli. - [BioAsset VC Dive: Predict Before You Test — Axiom and AI Toxicology](https://bioasset.info/research/bioasset-vc-dive-predict-before-you-test-axiom-and-ai-toxicology.html): Dmitry Vysotskiy. Profiles Axiom, a seed-stage San Francisco startup building AI models to predict drug liver toxicity in place of animal testing. - [AI x Drug Discovery: From Computation To Cure](https://bioasset.info/research/ai-x-drug-discovery-from-computation-to-cure.html): Dmitry Vysotskiy. Reviews how AI is being used in drug discovery, with examples from Insilico Medicine, Variant Bio, GSK and AstraZeneca. - [BioAsset Autopsies: The Intarcia Story](https://bioasset.info/research/bioasset-autopsies-the-intarcia-story.html): Dmitry Vysotskiy. Examines why Intarcia Therapeutics collapsed after raising $1.9 billion for its ITCA 650 diabetes implant and receiving two FDA rejections. - [BioAsset Weekly: The Pricing Wars, Regulation and M&A](https://bioasset.info/research/bioasset-weekly-the-pricing-wars-regulation-and-m-a.html): Dmitry Vysotskiy. Covers the TrumpRx.gov launch, the Novo Nordisk and Eli Lilly outlook, FDA pressure on Hims & Hers, and GSK's purchase of Rapt Therapeutics. - [Update: Revolution Medicines](https://bioasset.info/research/update-revolution-medicines.html): Brendan Seo. Revolution Medicines reported positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer at the 2026 ASCO Annual Meeting. - [Parasites as Biotech Assets: From Disease to Drug Discovery](https://bioasset.info/research/parasites-as-biotech-assets-from-disease-to-drug-discovery.html): Brendan Seo. Explains how molecules that parasites use to evade the immune system are being studied as starting points for autoimmune and cancer drugs. - [Replimune’s Stock Crash After FDA Rejection](https://bioasset.info/research/replimune-s-stock-crash-after-fda-rejection.html): Brendan Seo. Replimune's stock fell about 19% in one session after the FDA again rejected its cancer therapy for insufficient evidence of effectiveness. - [Atavistik Bio: $160M to Drug the Undruggable and Cure a Rare Blood Disorder](https://bioasset.info/research/atavistik-bio-160m-to-drug-the-undruggable-and-cure-a-rare-blood-disorder.html): Jingqiu Tian. Atavistik Bio has raised $160 million in Series B funding to develop allosteric drugs, led by ATV-1601 for the bleeding disorder HHT. - [Alternative Prostate Cancer Treatment: Targeting Thyroid Hormone Receptors](https://bioasset.info/research/alternative-prostate-cancer-treatment-targeting-thyroid-hormone-receptors.html): Jingqiu Tian. A 2025 paper suggests blocking a thyroid hormone receptor with the compound NH-3 could treat prostate cancer that resists androgen therapy. - [Treating the Impossible: Novel Treatments Potentially Curing Type 1 Diabetes](https://bioasset.info/research/treating-the-impossible-novel-treatments-potentially-curing-type-1-diabetes.html): Jingqiu Tian. Surveys recent type 1 diabetes treatments, from the antibody teplizumab to stem cell-derived islet transplants and gene editing. - [Update: BMS x Anthropic](https://bioasset.info/research/update-bms-x-anthropic.html): Alay Galvankar. Bristol Myers Squibb struck a deal with Anthropic to roll out Claude to more than 30,000 employees across the company. - [Growth: Radioisotope Supply Boost](https://bioasset.info/research/growth-radioisotope-supply-boost.html): Alay Galvankar. Niowave has broken ground on a $75 million Actinium-225 production facility in Lansing, Michigan, expected to come online in 2028. - [Update: Replimune Stock Surges](https://bioasset.info/research/update-replimune-stock-surges.html): Alay Galvankar. Replimune shares rose over 90% after the company aligned with the FDA on a path to resubmit its application for RP1. - [Novo X Hims: From Lawsuit to Partnership — What It Means for GLP-1](https://bioasset.info/research/novo-x-hims-from-lawsuit-to-partnership-what-it-means-for-glp-1.html): Alay Galvankar. Novo Nordisk dropped its lawsuit against Hims & Hers and struck a deal for Hims to sell Novo's branded GLP-1 medicines on its platform. - [Fast-Tracked: How Hernexeos Won FDA Approval in 44 Days](https://bioasset.info/research/fast-tracked-how-hernexeos-won-fda-approval-in-44-days.html): Alay Galvankar. Boehringer Ingelheim's lung cancer pill Hernexeos won FDA approval 44 days after receiving a national priority voucher under the CNPV program. - [BioAsset VC Dive: Xaira Therapeutics — Can AI Crack the Drug Discovery Code?](https://bioasset.info/research/bioasset-vc-dive-xaira-therapeutics-can-ai-crack-the-drug-discovery-code.html): Alay Galvankar. Profiles Xaira Therapeutics, an AI-native drug discovery company founded in 2024 that launched with more than $1 billion in capital. - [Regeneron x CytomX](https://bioasset.info/research/regeneron-x-cytomx.html): Neev Mohindroo. Regeneron expanded its collaboration with CytomX in a licensing deal worth $37 million upfront and up to $4 billion in milestones. - [Lilly Neuroscience](https://bioasset.info/research/lilly-neuroscience.html): Neev Mohindroo. Eli Lilly expanded in neuroscience by acquiring Centessa for up to $7.8 billion and partnering with BioArctic on brain drug delivery. - [All Eyes On Cancer Therapy](https://bioasset.info/research/all-eyes-on-cancer-therapy.html): Sharath Venkatesan. The 2026 ASCO Annual Meeting opened in Chicago with attention on Revolution Medicines' pipeline and bispecific antibodies. - [The Cost of Uncertainty: uniQure’s Battle with the FDA](https://bioasset.info/research/the-cost-of-uncertainty-uniqure-s-battle-with-the-fda.html): Sharath Venkatesan. uniQure's Huntington's gene therapy AMT-130 was set back when the FDA reversed prior guidance and demanded a Phase 3 trial before filing. ## Team - Dmitry Vysotskiy, Founder & President (NYU Stern, Finance & Quantitative Economics) - Alay Galvankar, Lead Analyst & Vice President (NYU, Global Public Health & Biology) - Joy Wu, Lead Analyst (NYU, Biology & Business Studies) - Brendan Seo, Research Analyst (NYU, Economics) - Jingqiu Tian, Research Analyst (University of Cambridge, Biological Natural Sciences) - Yaz Arulthasan, Outreach (NYU, Biology) - Benjamin Shar, Research Analyst (NYU Stern, Finance) - Sharath Venkatesan, Research Analyst (NYU, Biochemistry) - Neev Mohindroo, Research Analyst (Rutgers University, Finance) - Viren Jain, Research Analyst (NYU CAS, Economics) - Judy Dalati, Research Analyst (NYU CAS, Global Public Health & Biology) - Olga Spasic, Research Analyst (NYU, Biology) ## Expert interviews - **Dr. Omar B. Lateef**, President & CEO, RUSH University System for Health (upcoming conversation) - **Sofia Axelrod**, Co-Founder & CEO, Circadian OS: Circadian medicine, optimizing cancer treatment timing, and translating circadian rhythm research into clinical impact - **Jay Schiff**, Addinex Technologies: Medtech innovation, bringing devices from concept to commercialization - **Andy Bolt**, Deloitte Life Sciences: How consulting intersects with biopharma strategy, and navigating a non-linear career path - **Dr. Ron Marks**, Biostatistician: The role of statistics in drug development, clinical trial design, and interpreting endpoint data - **Annika Lundström**, Co-Founder & CEO, ReMinded: Building a cortisol biotech startup - **Dr. Ayoub Glia**, Scientist & Engineer, AMMLab, NYU Abu Dhabi: Microfluidic innovation, paper-based diagnostics, 3D tumor models, and accessible biomedical engineering for global health - **Dr. Paul Glimcher**, Professor of Neuroscience & Economics, NYU: Neuroeconomics, decision-making under uncertainty, and the convergence of neuroscience and finance - **Dr. Michele Pagano**, Chair, Department of Biochemistry & Molecular Pharmacology, NYU: Cell cycle control, ubiquitin-proteasome system, and translating fundamental research into oncology drug discovery - **Dr. Hao Su**, Director, Biomechatronics & Intelligent Robotics Lab, NYU Tandon: AI-powered wearable robotics, exoskeletons, and minimally invasive surgical robots transforming rehabilitation and medical procedures ## Site sections - [Insights](https://bioasset.info/#/insights): all research as slides - [Research articles](https://bioasset.info/research/): every post as an article - [Conversations](https://bioasset.info/#/conversations): expert interviews - [Fall 2026](https://bioasset.info/#/fall-2026): the 11-week curriculum - [Clients](https://bioasset.info/#/clients) and [Partnerships](https://bioasset.info/#/partnerships): ReMinded - [Our Team](https://bioasset.info/#/team) and [Advisory Board](https://bioasset.info/#/advisory) - [Collaborate](https://bioasset.info/#/collaborate) and [Join](https://bioasset.info/#/join) ## Optional - [Full site text](https://bioasset.info/llms-full.txt): everything on the site in one file, including the full text of every research post - [Long Aktis Oncology (AKTS): Investment Pitch (PDF)](https://bioasset.info/files/Long-Aktis-Oncology-Pitch.pdf) - [Tectonic Therapeutic (TECX): Long Thesis Memo & Financial Model (PDF)](https://bioasset.info/files/TECX-Memo-Benjamin-Shar.pdf)